Federated Hermes
VRDN icon

Federated Hermes’s Viridian Therapeutics VRDN Stock Holding History

Federated Hermes’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.1M Buy
668,968
+252,610
+61% +$7.5M 0.02% 568
2025
Q4 		$13M Buy
416,358
+416,226
+315,323% +$11.4M 0.02% 558
2025
Q3 		$2.85K Buy
132
+13
+11% +$234 ﹤0.01% 2001
2025
Q2 		$1.66K Buy
+119
New +$1.61K ﹤0.01% 1969
2023
Q2 		– Sell
-77,342
Closed -$1.97M – 2230
2023
Q1 		$1.97M Buy
77,342
+56,507
+271% +$1.81M 0.01% 961
2022
Q4 		$609K Buy
+20,835
New +$480K ﹤0.01% 1301
2020
Q2 		– Sell
-92
Closed -$1K – 2386
2020
Q1 		$1K Buy
+92
New +$1.07K ﹤0.01% 2160

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return